What happened with COSM today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Cosmos Holdings Inc. supplies prescription medicines, over-the-counter drugs and other healthcare products that pharmacies and distributors buy for resale. Its subsidiary Cosmofarm handles the wholesale business, which brings in most of the group's revenue. Almost all revenue comes from Greece.
The company also manufactures generic medicines through CANA and sells its own supplement brands, Sky Premium Life and Mediterranation. Doc Pharma exclusively manufactures those supplements. Manufacturing and own-brand sales are smaller businesses than wholesale, but carry higher margins.
A relatively small group of pharmaceutical wholesalers accounts for a significant share of sales, giving those buyers influence over pricing. One wholesaler also holds exclusive rights to promote and distribute Sky Premium Life in Greece. Wholesale operations depend on licensing: subsidiary SkyPharm's Greek wholesale pharmaceutical licence expired, and the regulator rejected its renewal application.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Cosmos Holdings Inc.’s results chiefly depend on Greek pharmaceutical wholesale volumes, while Doc Pharma supplies its proprietary nutraceuticals and licenses cancer-treatment patents.
Cencora offers a European comparison for Cosmos Holdings Inc.: both sell medicines to healthcare customers, with Cosmos focused on Greek pharmacies. Watch Cencora’s European pharmaceutical wholesale business for clues about prescription demand and wholesale margins.
ZeroStack Corp. shares Cosmos Holdings Inc.’s exposure to European medicine demand and cross-border wholesale margins: its German subsidiary Phatebo imports and exports medicines, while Cosmos sells to pharmacies and wholesalers and exports pharmaceuticals. Watch ZeroStack’s Commercial and Wholesale business, rather than its Digital Assets and AI business, for this comparison.
Cardinal Health provides a comparison for Cosmos Holdings Inc.’s medicine-distribution business, but its pharmaceutical sales serve the United States while Cosmos is concentrated in Greece. Both sell prescription and over-the-counter medicines to pharmacies and healthcare providers; Cardinal’s Pharma results are the relevant place to watch prescription volumes and distribution margins.
McKesson is a wholesale-business comparison rather than a close geographic rival for Cosmos Holdings Inc.: both sell branded, generic and over-the-counter medicines to pharmacies, but McKesson serves North America while Cosmos is concentrated in Greece. Its North American Pharmaceutical results offer a comparison for generic-drug pricing and distribution margins, not Greek pharmacy demand.
Fed Interest Rate Decision
Fed rate decisions matter to Cosmos Health because higher or lower U.S. interest rates can change what it pays on its mostly floating-rate loans and how much cash debt service uses.
Expected4.0%Last release4.0%
If it comes in above expectations
If higher U.S. rates lift interest on Cosmos Health’s floating-rate loans, the company may have less cash for its pharmaceutical wholesale, manufacturing and own-brand operations.
If it comes in below expectations
If lower U.S. rates reduce interest on Cosmos Health’s floating-rate loans, debt service may use less cash, leaving more available for its pharmaceutical wholesale, manufacturing and own-brand operations.
Cencora, Inc. earningsCOR
Cencora’s report will show what European medicine demand and wholesale margins look like, offering a comparison for Cosmos Health’s Greece-focused wholesale business.
Look at sales and margins in Cencora’s European pharmaceutical wholesale business. Steady demand with margins holding would suggest European distributors can still earn a return on medicine sales, a favorable comparison for the wholesale business that dominates Cosmos Health. Weaker sales or thinner margins would signal greater demand or pricing pressure for distributors, a risk to Cosmos’s main revenue source, though the U.S. and Greek markets are not the same.
Cosmos Holdings Inc. earningsThis company
Cosmos Health’s report will show whether its pharmaceutical manufacturing and own-brand products are adding enough profit beyond wholesale to help cover the company’s operating costs.
Read revenue from wholesale, pharmaceutical manufacturing and own-brand products alongside gross margin, then check the operating loss and cash used in operations. If manufacturing and own-brand sales grow, margins improve, and losses and operating cash use ease, the changing mix is contributing more toward operating costs and funding needs. If growth still comes mainly from wholesale while margins stall and losses or cash use rise, sales have not yet translated into enough profit and cash.
